RxDoctor Payments Data

Ekaterina Yavarovich, DO

Critical Care Medicine · Houston, TXNPI 1306251079

Payments from drug & device makers

$2,388in general payments, 2019–2025

Across 19 payments — averaging $125.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$930
  • Intuitive Surgical$878
  • Boston Scientific$200
  • Mallinckrodt Hospital Products Inc.$142
  • Pinnacle Biologics, Inc$61
  • Steris Corporation$60
  • plus $117 from 3 others

What the payments were for

  • Speaking & faculty fees$2008%
  • Travel & lodging$1,51163%
  • Food & beverage$67728%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,388 in reported general payments places this provider in the 75th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$131,858
Medicare patients
521
Services billed
1,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate20$253,248
NucalaMepolizumab17$63,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$42,681
Breo ElliptaFluticasone/Vilanterol63$27,232
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$24,333
Incruse ElliptaUmeclidinium Bromide56$24,191
SymbicortBudesonide/Formoterol Fumarate23$7,491
Advair HfaFluticasone Propion/Salmeterol11$6,375
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$6,023
Albuterol Sulfate HfaAlbuterol Sulfate111$3,296
Wixela InhubFluticasone Propion/Salmeterol31$3,095
Ventolin HfaAlbuterol Sulfate34$2,427
Ipratropium Bromide68$2,233
Roflumilast32$1,731
Azithromycin116$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$38$7,49123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →